Payden & Rygel’s UnitedHealth UNH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-34,600
Closed -$10.8M 122
2025
Q2
$10.8M Buy
34,600
+11,820
+52% +$4.52M 0.89% 54
2025
Q1
$11.9M Sell
22,780
-5,600
-20% -$2.86M 1.03% 48
2024
Q4
$14.4M Buy
28,380
+23,800
+520% +$13.5M 1.24% 38
2024
Q3
$2.68M Hold
4,580
0.21% 72
2024
Q2
$2.33M Sell
4,580
-25,800
-85% -$12.6M 0.19% 72
2024
Q1
$15M Buy
30,380
+5,600
+23% +$2.85M 0.71% 51
2023
Q4
$13M Hold
24,780
0.91% 59
2023
Q3
$12.5M Sell
24,780
-37,050
-60% -$18.2M 0.85% 55
2023
Q2
$29.7M Sell
61,830
-11,100
-15% -$5.43M 2.1% 3
2023
Q1
$34.5M Sell
72,930
-22,280
-23% -$10.8M 2.04% 10
2022
Q4
$50.5M Buy
95,210
+1,100
+1% +$583K 2.69% 1
2022
Q3
$47.5M Buy
94,110
+2,400
+3% +$1.26M 2.78% 2
2022
Q2
$47.1M Buy
91,710
+700
+0.8% +$352K 2.83% 2
2022
Q1
$46.4M Buy
91,010
+34,300
+60% +$16.5M 2.34% 5
2021
Q4
$28.5M Buy
56,710
+1,110
+2% +$502K 1.32% 33
2021
Q3
$21.7M Buy
55,600
+7,700
+16% +$3.19M 1.13% 46
2021
Q2
$19.2M Buy
47,900
+2,000
+4% +$797K 0.91% 67
2021
Q1
$17.1M Buy
+45,900
New +$15.9M 0.79% 68
2016
Q1
Sell
-191
Closed -$22K 211
2015
Q4
$22K Buy
+191
New +$22.3K ﹤0.01% 133

Other funds holding UNH

Payden & Rygel's UNH Position: Q3 2025 in Review

Payden & Rygel sold out of UnitedHealth (UNH) in Q3 2025, closing a stake of 34,600 shares — an estimated $10.8M sold.

Payden & Rygel first reported a position in UNH in Q4 2015 and held it in 19 quarters. The position peaked at $50.5M in Q4 2022. 3,159 funds tracked by Wall St. Rank hold UNH as of Q3 2025.

  • Payden & Rygel reported no remaining UnitedHealth position as of Q3 2025 after selling out during the quarter.
  • Payden & Rygel sold 34,600 UnitedHealth shares in Q3 2025, an estimated $10.8M.
  • Payden & Rygel first reported a position in UnitedHealth in Q4 2015 and held it in 19 quarters.
  • Payden & Rygel's UnitedHealth position peaked at $50.5M in Q4 2022.
  • 3,159 funds tracked by Wall St. Rank held UnitedHealth as of Q3 2025.

Based on Payden & Rygel's 13F filing for Q3 2025, filed 10 Nov 2025.